Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced that an abstract on its most advanced product candidate, ANG1005, has been selected for presentation at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference being held October 20-22, 2013 in Boston, MA.
Help employers find you! Check out all the jobs and post your resume.
